We would like to thank our shareholders for their continued support.

During the current interim consolidated accounting period, in Japan, although sales of Medical Gloves and Urinary Drainage-related products decreased, sales of Closed Drug Mixing/Infusion Systems, which we are promoting as a priority business, and Dysphagia-related products, for which demand is expanding, continued to grow. In overseas markets, while sales of AV Fistula Needles remained strong, sales of Blood Bags and Apheresis Kits for North America decreased.

As a result, net sales for this consolidated fiscal year decreased by 3,904 million yen from the previous consolidated fiscal year to 65,845 million yen (down 5.6% year-over-year).

Regarding profits, although the effect of increased sales of AV Fistula Needles, Closed Drug Mixing/Infusion Systems, and Dysphagia-related products contributed, the impact of decreased sales of Blood Bags and Apheresis Kits resulted in operating profit of 381 million yen, down by 491 million yen from the previous consolidated fiscal year (down 56.3% year-over-year). While equity in earnings of affiliates was recorded, interest expenses and foreign exchange losses were posted, resulting in ordinary profit of 356 million yen (down 30.8% year-over-year). Furthermore, as part of structural reforms to reorganize overseas production bases, business restructuring losses were recorded as extraordinary losses at the Korean production facility, resulting in net loss attributable to owners of the parent of 783 million yen (compared to net profit of 89 million yen in the previous fiscal year).

In accordance with our basic policy on profit distribution, we have decided to pay a dividend of 8.5 yen per share.

We would like to ask our shareholders for their continued support and cooperation.

May 2026